Related Experiment Video

Updated: Aug 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Atrial fibrillation: reducing stroke risk with low-dose anticoagulation

J E Dalen1

  • 1College of Medicine, University of Arizona, Tucson.

Geriatrics
|May 1, 1994
PubMed

Insights

Atrial fibrillation (AF) increases stroke risk, but oral anticoagulants like warfarin can safely prevent embolic strokes in patients with AF. A target INR of 2.0 to 3.0 is recommended for effective treatment with reduced bleeding risk.

Area of Science:

  • Cardiology
  • Neurology
  • Geriatrics

Background:

  • Atrial fibrillation (AF) is a major risk factor for systemic embolism, with incidence increasing significantly with age.
  • AF commonly co-exists with hypertension, coronary heart disease, and congestive heart failure, compounding patient risk.
  • The prevalence of AF in Americans over 75 reaches 12-16%.

Purpose of the Study:

  • To review the efficacy and safety of oral anticoagulants in patients with atrial fibrillation.
  • To outline current recommendations for anticoagulation therapy in AF patients.

Main Methods:

  • Analysis of five clinical trials published since 1989 evaluating oral anticoagulants in AF patients.
  • Review of recommendations from the American College of Chest Physicians (ACCP).

Main Results:

  • Oral anticoagulants significantly and safely reduce the risk of embolic stroke in patients with AF.
  • Long-term warfarin therapy is recommended for AF patients with cardiovascular disease, thyrotoxicosis, or age 60+.
  • An INR range of 2.0 to 3.0 is effective and associated with less bleeding compared to high-intensity treatment.

Conclusions:

  • Anticoagulation therapy is crucial for managing stroke risk in atrial fibrillation patients.
  • Warfarin therapy within a specific INR range offers a favorable balance of efficacy and safety.
  • These findings support current guidelines for AF management.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...